报价延迟最少15分钟:2026/07/10 20:16 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
21.06 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-0.32/-1.19
|
|
企业价值
3.56B
|
| 资产负债 |
|
每股账面净值
1.35
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
276.98M
|
|
每股收益
1.18
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product,clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment. |
